Skip to main content

Profile hero

Profile details

About Joshua Samuel

Josh is an associate focusing on the representation of life sciences companies on corporate, transactional, and commercial matters.

Recent work

  • AbbVie on its collaboration and option agreement with Parvus Therapeutics to develop and commercialize treatments for IBD, utilizing Parvus’ proprietary NavacimTM platform technology.
  • Roivant Sciences on its $7.1bn sale of Telavant to Roche.
  • Novartis, as global transaction counsel, on the separation and spin-off of Sandoz, its generics and biosimilars division. 
  • Moderna on a strategic collaboration and license of CytomX's Probody technology for use with Moderna's mRNA therapeutics, including a $35 million upfront cash payment and up to $1.2 billion in milestones.
  • Alexion, AstraZeneca Rare Disease on its acquisition of LogicBio® Therapeutics, Inc.
  • Novartis in its acquisition of DTx Pharma, a biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications.



  • Columbia Law School
    • J.D., 2021
  • Texas A&M University
    • B.A., summa cum laude, 2018

Bar Admission

  • Admitted to the New York State Bar